Abbott Gets Into Hot Water
Executive Summary
The $100 million consent decree that Abbott Diagnostics signed with the Food and Drug Administration in early November took many in the diagnostics industry by surprise and has left them shaken.
You may also be interested in...
Diagnostic Products Corp.: Thriving, For Now
The popularity of DPC's random-access immunoassay system, the Immulite 2000, has helped the company become a significant player in the highly competitive automated immunoassay market. But DPC's benefited from some good luck--namely the misfortunes of top player Abbott Diagnostics and the slow efforts by other competitors to step into the gap left by Abbott. DPC's dilemma is whether it can maintain its narrow focus as Abbott re-emerges and other competitors get stronger.
Diagnostic Products Corp.: Thriving, For Now
The popularity of DPC's random-access immunoassay system, the Immulite 2000, has helped the company become a significant player in the highly competitive automated immunoassay market. But DPC's benefited from some good luck--namely the misfortunes of top player Abbott Diagnostics and the slow efforts by other competitors to step into the gap left by Abbott. DPC's dilemma is whether it can maintain its narrow focus as Abbott re-emerges and other competitors get stronger.
Lonza Biologics: Responding to Changing Needs
Biologics contract manufacturing is changing rapidly. To maintain its leading position, Lonza Biologics is adopting a more flexible and responsive approach in its dealmaking.